Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
Today 10:09 EST
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
November 18, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
November 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
October 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
October 24, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
October 10, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Third Quarter Financial Results
October 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
September 25, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Completes Acquisition of Escient Pharmaceuticals
May 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
May 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.